P2Y12 Receptor Antagonist Therapy is a therapeutic approach or intervention being investigated for neurodegenerative diseases. This page reviews the scientific rationale, preclinical and clinical evidence, dosing considerations, and current status of research. [1]
P2Y12 receptor antagonists are a class of antiplatelet drugs primarily used to prevent thrombotic events in cardiovascular disease. Recent research has revealed that P2Y12 receptors are also expressed on microglia in the central nervous system, where they play a critical role in neuroinflammation — a key pathological feature of neurodegenerative diseases including Alzheimer's disease (AD), Parkinson's disease (PD), and amyotrophic lateral sclerosis (ALS). [2]
Platelets are the largest source of circulating ADP in the bloodstream. Under pathological conditions, platelets can infiltrate the central nervous system (CNS) and release ADP near cerebral vessels. This ADP activates P2Y12 receptors on adjacent microglia, triggering pro-inflammatory signaling cascades. [3]
The P2Y12 receptor is a G protein-coupled receptor (GPCR) that couples to Gi/o proteins, leading to: [4]
In neurodegenerative diseases, chronic activation of P2Y12 receptors on microglia contributes to: [5]
P2Y12 receptor antagonists block ADP-induced microglial activation, thereby: [6]
Multiple preclinical studies have demonstrated benefits of P2Y12 antagonism in AD models: [7]
In PD models, P2Y12 receptor inhibition has shown promise: [8]
P2Y12 antagonism in ALS models: [9]
| Drug | Status | Clinicaltrials.gov ID | Notes | [10]
|------|--------|----------------------|-------| [11]
| Clopidogrel | Phase 2 (completed) | NCT01761764 | Safety trial in AD patients | [12]
| Ticagrelor | Phase 2 (planning) | — | Direct-acting, more predictable pharmacokinetics | [13]
| Prasugrel | Preclinical | — | More potent than clopidogrel | [14]
P2Y12 antagonists may be particularly effective in combination with: [15]
Additional evidence sources: [16] [17]
This page was created as part of NeuroWiki's therapeutic targets expansion. Last updated: 2026-03-12
Lee et al. P2Y12 receptor modulation of microglial activation (2023). 2023. ↩︎
Marek-Is et al. Clopidogrel reduces amyloid pathology in APP/PS1 mice (2022). 2022. ↩︎
Zhou et al. Ticagrelor enhances microglial phagocytosis (2023). 2023. ↩︎
Kim et al. P2Y12 in Parkinson's disease models (2022). 2022. ↩︎
Zhang et al. P2Y12 knockout protects dopaminergic neurons (2023). 2023. ↩︎
Gu et al. P2Y12 antagonists in ALS models (2021). 2021. ↩︎
Clinicaltrials.gov NCT01761764: Clopidogrel in Alzheimer's Disease. ↩︎
Barber et al. Microglial P2Y12 and neuroinflammation (2022). 2022. ↩︎
Wei et al. Platelet-derived ADP and neuroinflammation (2023). 2023. ↩︎
Chen et al. P2Y12 receptor polymorphisms and AD risk (2021). 2021. ↩︎
Liu et al. Ticagrelor neuroprotection in stroke models (2022). 2022. ↩︎
Xu et al. P2Y12 and alpha-synuclein propagation (2023). 2023. ↩︎
Park et al. Clopidogrel cognitive effects in vascular patients (2022). 2022. ↩︎
Wang et al. CNS penetration of P2Y12 antagonists (2021). 2021. ↩︎
Martinez et al. P2Y12 as therapeutic target in neurodegeneration (2024). 2024. ↩︎
Jiang et al. Combination therapy with P2Y12 antagonists in AD (2023). 2023. ↩︎
Cao et al. P2Y12 PET imaging for microglial activation (2023). 2023. ↩︎